Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 , a Phase 2-Ready Third-Generation Anti-CD40L Antibody
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
QIMC Confirms Thermogenic Natural Gas in Its Nova Scotia Multi-Gas System Through Independent Isotope Analysis and Defines a Total of Five High-Concentration Target Zones Including Clean Natural Hydrogen Target Zones at West-Advocate and Bennett Hill
Gemdale Gold Reports Strong Metallurgical Test Results at its Pontio Gold Project: Gold Recoveries of +91% and Copper Recoveries up to 87.5%
Davidson River Drilling Doubles Thunderbird Corridor Width, Intersects Dravite-Clay Alteration Across All Tested Trends
